2013 SCK•CEN annual report: interview with E. D'Agostino

With 12.6 million new cases and 7.5 million deaths each year, cancer remains a major public health issue. Some 50 to 60% of patients undergo radiotherapy, sometimes in combination with surgery or drugs, as part of their treatment. DoseVue NV, the first spin-off at SCK •CEN, is developing technology to make high-dose radiotherapy more accurate and efficacious. Emiliano D’Agostino is one of the two founding partners of DoseVue, a promising new firm based in Hasselt (continue on page 85)

Click here to read the full article

(source: www.sckcen.be)